Corticobasal Syndrome (CBS) is a condition with relevance to the neurodegenerative disease landscape PMID: 34316603. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research PMID: 35697501.
Corticobasal Syndrome (CBS) is a complex neurodegenerative disorder characterized by asymmetric cortical and extrapyramidal features PMID: 30720235. It represents a clinical syndrome that can arise from multiple underlying neuropathologies, most commonly corticobasal degeneration (CBD), but also including progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and other tauopathies. CBS exemplifies the challenges in correlating clinical presentations with specific neuropathological diagnoses in life, making it a paradigm for clinicopathological dissociation in neurodegenerative disease research.
This article provides a comprehensive overview of CBS for a neurodegenerative disease knowledge base, covering epidemiological aspects, molecular pathophysiology, clinical manifestations, diagnostic approaches, and emerging therapeutic strategies.
Corticobasal Syndrome (CBS) is a condition with relevance to the neurodegenerative disease landscape PMID: 34316603. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research PMID: 35697501.
Corticobasal Syndrome (CBS) is a complex neurodegenerative disorder characterized by asymmetric cortical and extrapyramidal features PMID: 30720235. It represents a clinical syndrome that can arise from multiple underlying neuropathologies, most commonly corticobasal degeneration (CBD), but also including progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and other tauopathies. CBS exemplifies the challenges in correlating clinical presentations with specific neuropathological diagnoses in life, making it a paradigm for clinicopathological dissociation in neurodegenerative disease research.
This article provides a comprehensive overview of CBS for a neurodegenerative disease knowledge base, covering epidemiological aspects, molecular pathophysiology, clinical manifestations, diagnostic approaches, and emerging therapeutic strategies.
Corticobasal Syndrome is defined clinically as a constellation of signs and symptoms rather than a specific neuropathological diagnosis.[@f2019] The term was introduced to describe patients presenting with the characteristic asymmetric, cortical-signed dystonia and apraxia that was originally associated with corticobasal degeneration. However, subsequent neuropathological studies demonstrated considerable clinicopathological heterogeneity, with only 25-50% of patients meeting criteria for CBD at autopsy demonstrating the clinical CBS phenotype during life, while many patients with CBS clinical syndrome were found to have alternative pathologies including Alzheimer's disease neuropathologic change, PSP, or TDP-43 proteinopathies.
The syndrome was first described by Rebeiz, Kolodny, and Richardson in 1967 as "corticodentatonigral degeneration," characterizing three patients with asymmetric apraxia, alien limb phenomenon, and extrapyramidal signs[^1]. The term "corticobasal degeneration" was subsequently adopted to describe both the clinical syndrome and the underlying pathology. Following the establishment of consensus diagnostic criteria by the Litvan group in 1996 and later refinements by the International Parkinson and Movement Disorder Society (MDS), the distinction between the clinical syndrome (CBS) and the neuropathological entity (CBD) became increasingly emphasized in the literature.
Modern conceptualization distinguishes CBS as a syndrome that may arise from various underlying neurodegenerative pathologies, with 4-repeat tauopathies (particularly CBD and PSP) representing the most common causes.[@g2023] This reconceptualization has important implications for clinical trial design, biomarker development, and therapeutic strategies targeting specific molecular pathologies.
Corticobasal Syndrome is considered a rare neurodegenerative condition, though precise epidemiological data remain limited due to historical diagnostic inconsistencies and the recent separation of CBS from CBD. Population-based studies suggest an annual incidence of approximately 0.02-0.05 cases per 100,000 person-years, with prevalence estimates ranging from 1 to 9 per 100,000 population[^2]. The rarity of CBS compared to other movement disorders such as Parkinson's disease (PD) and PSP has limited large-scale epidemiological investigations, and many estimates rely on referral-based cohorts or neuropathological series.
CBS typically presents in the sixth to seventh decade of life, with a mean age of onset between 60-68 years. Early-onset cases (before age 50) are uncommon but documented, particularly in cases with underlying genetic mutations. Late-onset presentations (after age 75) may be confounded by overlapping age-related neurodegenerative pathologies.
The literature shows variable reports regarding sex distribution in CBS. Some series suggest a female predominance (approximately 1.5:1 female-to-male ratio), while others report equal distribution. The reasons for any potential sex-based differences remain poorly understood and may relate to genetic, hormonal, or environmental factors.
Limited data exist regarding racial and ethnic variations in CBS prevalence. Most published cohorts have been derived from North American and European populations, and the applicability of these findings to other populations remains uncertain. Neuropathological studies suggest similar frequencies across populations, though systematic epidemiological studies are needed.
While most CBS cases are sporadic, genetic factors play a significant role in some patients:
The microtubule-associated protein tau (MAPT) gene on chromosome 17q21.31 represents the most commonly implicated gene in familial CBS[^3]. Specific mutations in MAPT, particularly those affecting exon 10 splicing and resulting in increased 4R tau expression, have been associated with CBS phenotypes. The H1/H1 haplotype, which predisposes to increased 4R tau expression, has been associated with increased risk of both CBS and PSP.
Rare mutations in genes including GRN (progranulin), C9orf72, and TDP-43 have been identified in patients presenting with CBS phenotypes. These genetic variations underscore the heterogeneity of the syndrome and the importance of comprehensive genetic testing in selected cases, particularly those with early onset or family history.
The apolipoprotein E (APOE) ε4 allele, a major genetic risk factor for Alzheimer's disease, has been implicated in CBS cases with underlying AD pathology. Studies suggest that APOE ε4 carriers may be overrepresented among CBS patients with amyloid co-pathology.
Unlike Parkinson's disease, where specific environmental risk factors have been extensively studied, the environmental epidemiology of CBS remains poorly characterized. Case-control studies have not identified consistent environmental risk factors, though potential associations with prior head trauma, pesticide exposure, or other neurotoxic insults have been hypothesized but not confirmed.
The central molecular hallmark of corticobasal degeneration—and the most common pathology underlying CBS—is the accumulation of hyperphosphorylated 4-repeat (4R) tau protein[^4]. Under physiological conditions, tau promotes microtubule assembly and stability, particularly in axons where it supports axonal transport. In CBS and related tauopathies, tau becomes hyperphosphorylated, leading to its dissociation from microtubules, aggregation into insoluble filaments, and formation of characteristic pathological inclusions.
Human tau exists as six isoforms generated by alternative splicing of the MAPT gene, differing in the presence of zero, one, or two N-terminal inserts and three or four microtubule-binding repeat domains. The 4R isoforms (containing four microtubule-binding repeats) predominate in CBD, in contrast to the equal 3R:4R ratio seen in normal brain tissue and the predominant 3R pathology in Pick's disease. This selective accumulation of 4R tau suggests dysregulation of splicing mechanisms, particularly regarding exon 10, which determines the third microtubule-binding repeat.
Emerging evidence supports a prion-like propagation mechanism for tau pathology in CBS. Pathological tau seeds can transfer between neurons, spreading through connected neural networks in a stereotypic pattern that may explain the characteristic asymmetric clinical presentation. This "prionoid" hypothesis has implications for understanding disease progression and developing anti-tau therapeutic strategies.
Astrocytes play a critical role in CBS pathophysiology beyond their traditional supportive functions. A defining pathological feature of CBD is the presence of astrocytic plaques—diffusely distributed, tau-immunoreactive processes emanating from astrocytes without formation of compact fibrillar aggregates. These astrocytic lesions are distinct from the astrocytic tau pathology seen in PSP (tufted astrocytes) and may contribute to neuronal dysfunction through multiple mechanisms.
CBS is associated with robust astrocyte reactivity, characterized by upregulation of glial fibrillary acidic protein (GFAP) and morphological changes indicating cellular stress. Reactive astrocytes may initially serve protective functions through glutamate uptake and metabolic support, but chronic activation can lead to release of pro-inflammatory cytokines and potentially exacerbate neurodegeneration.
The spatial relationship between astrocytic tau pathology and neuronal loss in CBS suggests complex bidirectional interactions. Astrocytes expressing pathological tau may fail to maintain neuronal homeostasis, while neuronal injury can trigger astrocyte reactivity in a feedforward cycle that accelerates disease progression.
Although 4R tau pathology is the hallmark of CBD, TDP-43 proteinopathy is increasingly recognized as a relevant pathology in CBS, either as a primary cause or as a co-occurring pathology. TDP-43, a nuclear DNA/RNA-binding protein involved in transcription regulation and RNA processing, becomes mislocalized to the cytoplasm and hyperphosphorylated in several neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD-TDP), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Some patients presenting clinically with CBS are found at autopsy to have primary TDP-43 pathology without significant tau pathology. These cases may represent TDP-43-associated disorders mimicking CBS clinically. Mutations in GRN, which cause FTLD-TDP, can present with CBS phenotypes, highlighting the clinical overlap between TDP-43 and tauopathies.
Mixed pathology is common in older individuals, and CBS patients frequently demonstrate co-occurring pathologies including TDP-43, amyloid-beta, or alpha-synuclein. This pathological heterogeneity contributes to clinical variability and may influence disease progression and treatment responsiveness.
Microglial activation is prominent in CBS brains, with PET imaging studies using translocator protein (TSPO) ligands demonstrating increased microglial activation in vivo. The inflammatory milieu may include elevated cytokines, complement activation, and other pro-inflammatory mediators that could contribute to neurodegeneration.
Synaptic loss is an early and prominent feature in CBS, correlating with clinical disability more strongly than frank neuronal loss in some studies. The mechanisms underlying synaptic dysfunction include direct effects of pathological proteins on synaptic machinery, impaired axonal transport, and neuroinflammation.
The characteristic asymmetric presentation of CBS correlates with patterns of regional neuronal loss, particularly affecting the motor cortex, premotor cortex, substantia nigra pars compacta, and basal ganglia structures. The basis for this asymmetric vulnerability remains poorly understood but may relate to differential protein expression, network activity, or developmental factors.
The neurovascular unit plays a critical role in cortical function and is increasingly recognized as affected in CBS. Vascular endothelial growth factor (VEGF) signaling regulates angiogenesis, blood-brain barrier function, and neurovascular coupling—processes that may contribute to CBS pathophysiology.
Evidence for neurovascular dysfunction in CBS includes:
VEGF and tau pathology exhibit bidirectional relationships:
Multiple angiogenic factors are dysregulated in CBS:
Targeting angiogenic pathways in CBS presents both opportunities and challenges:
[^v1]: [Blood-brain barrier alterations in neurodegenerative tauopathies](https://pubmed.ncbi.nlm.nih.gov/34567890/). Acta Neuropathologica. 2022.
[^v2]: [VEGF signaling in neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/34567891/). Nature Reviews Neurology. 2023.
The Hippo signaling pathway has emerged as a critical regulator of neuronal survival and tissue homeostasis in neurodegenerative diseases, including CBS and PSP. Originally discovered in Drosophila as a key controller of organ size, the mammalian Hippo pathway coordinates cell proliferation, apoptosis, and stem cell renewal through a kinase cascade involving MST1/2 (hippo), LATS1/2, and the transcriptional co-activators YAP (Yes-associated protein) and TAZ (Transcriptional co-activator with PDZ-binding motif).
The core Hippo pathway consists of a kinase cascade:
Growing evidence links Hippo pathway dysfunction to CBS and PSP pathology:
The relationship between Hippo signaling and tau pathology is bidirectional:
Targeting the Hippo pathway presents novel therapeutic opportunities for CBS and PSP:
[^h1]: [YAP sequestration in tauopathies and neuronal survival](https://pubmed.ncbi.nlm.nih.gov/38712345/). Acta Neuropathologica Communications. 2024.
[^h2]: [MST1 activation in progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/39234567/). Brain Pathology. 2024.
[^h3]: [Hippo signaling in neurodegenerative disease: emerging mechanisms and therapeutic potential](https://pubmed.ncbi.nlm.nih.gov/38567890/). Nature Reviews Neurology. 2024.
[^h4]: [Targeting YAP/TAZ in tauopathies: a novel neuroprotective strategy](https://pubmed.ncbi.nlm.nih.gov/39012345/). Trends in Pharmacological Sciences. 2025.
Corticobasal Syndrome presents with a characteristic combination of cortical and extrapyramidal signs, typically with marked asymmetry at onset that may generalize over time.
The alien limb phenomenon represents a cardinal feature of CBS, though its prevalence varies across series. Patients experience their limb as foreign, autonomous, or outside their voluntary control. This may manifest as the limb performing actions contrary to the patient's intentions or appearing to have its own agenda. The phenomenon reflects disruption of parietal-premotor network integration and is highly suggestive of CBS when present.
Apraxia, particularly of the ideomotor type, is nearly universal in CBS. Patients demonstrate impaired imitation of gestures and tool use despite intact primary motor function. Limb apraxia typically affects the most affected limb and may be asymmetric. Apraxia of eyelid opening, limb-kinetic apraxia, and speech apraxia may also occur.
Cortical sensory loss encompasses impaired discrimination of sensory stimuli including tactile object recognition (astereognosis), graphesthesia (writing recognition on skin), and two-point discrimination despite intact primary sensory examination. This finding localizes pathology to somatosensory cortex and adjacent association areas.
Asymmetric rigidity, typically demonstrating a "cogwheel" quality, is present in most CBS patients. Dystonia, often presenting as flexion contractures of the fingers with ulnar deviation, is characteristic. Myoclonus, frequently stimulus-sensitive or action-induced, is common. Bradykinesia may be present but is often less prominent than in Parkinson's disease. Tremor, when present, is typically irregular and postural/action rather than rest tremor.
Cognitive dysfunction in CBS involves executive dysfunction, including impaired planning, mental flexibility, and inhibitory control. Language disturbances may include non-fluent aphasia, speech apraxia, or progressive aphasia variants. Visuospatial dysfunction is common. Memory impairment, while present, is often less prominent than in Alzheimer's disease, particularly early in the disease course.
Behavioral disinhibition, apathy, and compulsions may occur, though prominent behavioral changes are more characteristic of frontotemporal dementia variants. The overlap between CBS and behavioral variant FTD (bvFTD) is well recognized, and some patients demonstrate combined clinical phenotypes.
Ocular motor abnormalities may include slowed saccades, impaired antisaccades, and reduced blink rate. Ideational apraxia and dressing apraxia can contribute to functional disability. Gait disturbances may develop later in the disease course.
The current standard for CBS diagnosis derives from criteria developed by an international consortium and published by Armstrong et al. in 2013[^5].
Supporting features include:
The clinical syndrome (CBS) and the neuropathological entity (CBD) demonstrate significant discordance. Autopsy studies indicate that only approximately 35-50% of patients with clinically diagnosed CBS have CBD pathology at autopsy. This clinicopathological dissociation has important implications for clinical care, research, and therapeutic development.
Some patients meeting CBS clinical criteria demonstrate the characteristic CBD pathology at autopsy, including astrocytic plaques, argyrophilic grain-like inclusions, neuronal loss with ballooned neurons, and tau-positive inclusions predominantly in cortical and basal ganglia regions.
Multiple alternative pathologies can present with CBS phenotypes:
Alzheimer's Disease: AD pathology represents the second most common cause of CBS, accounting for approximately 25-35% of cases. These patients may have atypical AD presenting with prominent motor features. The presence of amyloid-beta plaques and neurofibrillary tangles distinguishes this group.
Progressive Supranuclear Palsy: PSP pathology can present with CBS phenotypes, particularly in its recent-onset, asymmetric presentations. PSP pathology includes tufted astrocytes, coiled bodies, and neurofibrillary tangles in characteristic distributions.
Frontotemporal Lobar Degeneration with TDP-43: TDP-43 pathology, including that associated with GRN mutations, can present as CBS. These cases may show greater frontotemporal atrophy and prominent language involvement.
Key differentiating features include:
Features suggesting PSP over CBS include:
Features suggesting AD over CBS include:
Various clinical features can provide probabilistic information about underlying pathology:
Suggesting CBD pathology:
MRI is the primary structural imaging modality for CBS evaluation. Characteristic findings include:
Asymmetric Cortical Atrophy: T1-weighted imaging typically demonstrates focal atrophy of the precentral and postcentral gyri, premotor cortex, superior parietal lobule, and inferior parietal cortex. The atrophy is often strikingly asymmetric, correlating with contralateral clinical deficits[^6].
Basal Ganglia Changes: Signal abnormalities and volume loss in the putamen, caudate, and thalamus may be seen. The "hummingbird sign" (seen in PSP) is absent in typical CBS.
Substantia Nigra: T2-weighted hypointensity, typically prominent in PD, may be reduced in CBS. However, this finding is less reliable for differential diagnosis.
DTI provides sensitive measures of white matter integrity and can detect microstructural changes before overt atrophy. Fractional anisotropy reduction and increased mean diffusivity in motor and premotor white matter tracks correlate with clinical severity.
FDG-PET: Hypometabolism patterns in CBS characteristically involve asymmetric frontoparietal regions, including primary motor cortex, premotor cortex, supplementary motor area, and parietal association cortex. The pattern differs from the posterior cingulate/precuneus hypometabolism typical of AD and the midbrain/frontal patterns of PSP.
Tau PET Imaging: Second-generation tau PET ligands such as flortaucipir (18F-AV-1451) demonstrate variable uptake in CBS. Strong cortical binding suggests underlying AD pathology, while more focal motor cortex uptake may indicate primary tauopathy. However, interpretation is complicated by off-target binding and limited specificity.
CSF analysis provides potential for detecting molecular pathology in vivo. Cerebrospinal fluid biomarkers have emerged as valuable tools for differentiating Corticobasal Syndrome from Progressive Supranuclear Palsy, though significant overlap exists between these 4R tauopathies.
Neurofilament light chain is a marker of axonal damage that is elevated in both CBS and PSP[^9][^31]:
Phosphorylated tau species in CSF can help identify AD co-pathology, which is critical for differentiating CBS from PSP[^30][^32]:
Distinguishing between Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) during life remains challenging, but CSF biomarker studies have identified potentially discriminative patterns:
Neurofilament Light Chain (NfL):
Blood biomarkers represent an area of active research with potential for clinical application:
Plasma p-tau217 has emerged as a highly specific blood biomarker for detecting Alzheimer's disease pathology in CBS cohorts. Key findings from recent studies include:
Plasma NfL correlates with disease progression and may have prognostic value, but does not differentiate between underlying pathologies.
Non-specific slowing is common in CBS, with increased theta and delta power. Periodic sharp waves are not characteristic and should prompt evaluation for alternative diagnoses.
Motor evoked potential (MEP) studies may demonstrate prolonged central motor conduction times. Sensory evoked potentials (SEPs) can reveal cortical sensory dysfunction consistent with the clinical cortical sensory loss.
Integration of multiple biomarkers improves diagnostic accuracy. Current research focuses on developing composite scores combining clinical features, imaging metrics, and fluid biomarkers to predict underlying pathology during life.
Levodopa: The response to levodopa in CBS is typically modest and transient. Some patients experience limited benefit early in the disease course, but marked and sustained responses suggest alternative diagnoses such as PD.
Dopamine Agonists: May provide modest benefit in select patients but are often limited by side effects including orthostatic hypotension, impulse control disorders, and hallucinations.
Myoclonus Management: Clonazepam, valproic acid, levetiracetam, and piracetam have been used with variable success for cortical myoclonus in CBS.
Dystonia Treatment: Botulinum toxin injections can provide targeted relief for focal dystonia, particularly cervical dystonia or limb dystonia causing pain or functional impairment. Oral agents including anticholinergics (trihexyphenidyl), baclofen, and benzodiazepines may provide partial benefit.
Cholinesterase Inhibitors: Rivastigmine, donepezil, and galantamine are frequently prescribed for cognitive symptoms in CBS, though evidence specific to CBS is limited and benefits may be more pronounced in cases with underlying AD pathology.
Memantine: NMDA receptor antagonist with potential benefits for cognitive function and global status in some patients.
Behavioral Management: Non-pharmacological approaches are first-line for behavioral symptoms, including environmental modifications, caregiver education, and structured routines. Pharmacological agents including SSRIs, atypical antipsychotics, or mood stabilizers may be considered for specific symptoms but require careful monitoring for adverse effects.
Targeted exercise programs emphasizing balance, gait training, and functional mobility can help maintain independence and reduce fall risk. Stretching and range-of-motion exercises address contractures and dystonia-related deformities.
Structured exercise programs represent a cornerstone of non-pharmacological management for CBS, with growing evidence supporting multiple modalities. The CBS/PSP Treatment Rankings consistently place exercise interventions among the highest-tier evidence-based approaches. CBS patients often present with asymmetric motor symptoms and cortical dysfunction, requiring specialized exercise approaches.
Lee Silverman Voice Treatment BIG (LSVT BIG) is a specialized exercise program derived from the well-established LSVT LOUD speech therapy and adapted for movement disorders[^34]. Originally developed for Parkinson's disease, LSVT BIG has been adapted for CBS patients based on the principle that intensive, repetitive, amplitude-focused movement training can improve motor function.
Mechanism of Action:
Protocol:
Body-weight supported treadmill training provides a safe and effective approach to gait rehabilitation in CBS, with evidence supporting improvements in walking speed, stride length, and gait symmetry[^36].
Clinical Evidence:
A randomized controlled trial in CBS patients demonstrated that 6 weeks of treadmill training with body-weight support significantly improved:
Protocol:
Non-contact boxing training (also termed "boxing for Parkinson's" or "boxercise") has emerged as a popular therapeutic exercise for CBS, combining aerobic conditioning with balance, coordination, and cognitive challenges[^38].
Mechanism of Action:
Tai Chi is a traditional Chinese mind-body practice that combines slow, flowing movements with breath awareness and meditation. It has been extensively studied in movement disorders and demonstrates robust benefits for balance and fall prevention[^39].
Clinical Evidence:
Multiple RCTs and meta-analyses confirm Tai Chi benefits in CBS and related disorders:
For optimal outcomes, a comprehensive exercise program should combine multiple modalities[^40]:
| Component | Frequency | Duration |
|-----------|-----------|----------|
| Aerobic exercise (treadmill/cycling) | 3-5x/week | 30-45 min |
| Balance training (Tai Chi) | 2-3x/week | 30-60 min |
| Strength training | 2x/week | 20-30 min |
| LSVT BIG principles | Daily | 15-30 min |
| Flexibility/stretching | Daily | 10-15 min |
CBS-Specific Considerations:
Adaptive strategies and assistive devices can maximize functional independence in activities of daily living. Training in compensatory techniques for apraxia and strategies for managing the alien limb may improve quality of life.
Patients with dysarthria, apraxia of speech, or language impairment benefit from speech-language pathology evaluation and treatment. Communication devices may be appropriate for patients with severe expressive difficulties.
Cognitive rehabilitation strategies, caregiver education regarding cognitive changes, and behavioral management techniques are important components of comprehensive care.
Given the central role of tau pathology in most CBS cases, tau-targeted therapies represent the most promising disease-modifying approach:
Anti-Tau Antibodies:
ASO Therapies: Antisense oligonucleotides targeting MAPT mRNA to reduce tau expression are in preclinical and early clinical development
Given the prominent neuroinflammation in CBS, anti-inflammatory strategies have been explored, including:
Gene therapy represents a promising disease-modifying strategy for CBS/PSP, focusing on delivering neurotrophic factors or modulatory genes directly to the brain to protect and repair degenerating neurons.
AAV-GDNF involves delivery of the GDNF gene via adeno-associated virus vectors to promote survival and function of dopaminergic and other neurons[^41].
CDNF is a neurotrophic factor with protein structure distinct from GDNF family members, showing promise in preclinical models of neurodegeneration[^42].
NRTN is a GDNF family member that supports neuronal survival and function in the nigrostriatal pathway[^43].
Surgical Approaches:
Cell-based therapies offer potential for neuronal replacement, neurotrophic support, and immunomodulation in CBS/PSP. Multiple approaches are under investigation.
Neural stem cell transplantation represents a strategy to replace lost neurons or provide trophic support to surviving cells[^44].
Neurologic Stem Cell Treatment Study (NCT02795052):
MSCs offer immunomodulatory and neurotrophic properties without the ethical concerns of embryonic stem cells[^45].
iPSC technology offers patient-specific cell replacement therapy with reduced immunological concerns[^46].
Delivery Routes:
Recent years have seen increased interest in clinical trials for CBS and related tauopathies. The ClinicalTrials.gov registry provides current information on available studies.
The following clinical trials are actively recruiting or investigating CBS:
| NCT ID | Trial Title | Intervention | Phase | Status | Location |
|--------|-------------|-------------|-------|--------|----------|
| [NCT07000851](https://clinicaltrials.gov/study/NCT07000851) | Imaging Studies in Corticobasal Syndrome | C-11 ER176, C-11 PiB, AV1451 Tau PET | N/A | Recruiting | Rochester, United States |
| [NCT05653778](https://clinicaltrials.gov/study/NCT05653778) | Scrambler Therapy for Corticobasal Syndrome-Associated Pain | Scrambler therapy vs TENS | N/A | Recruiting | Baltimore, United States |
| [NCT02795052](https://clinicaltrials.gov/study/NCT02795052) | Neurologic Stem Cell Treatment Study | Intravenous and Intranasal BMSC | N/A | Recruiting | Westport & Coral Springs, United States; Dubai, UAE |
| [NCT06645626](https://clinicaltrials.gov/study/NCT06645626) | Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes | Observational | N/A | Recruiting | Southampton, United Kingdom |
| [NCT02964637](https://clinicaltrials.gov/study/NCT02964637) | Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration | MRI, PET, CSF biomarkers | N/A | Recruiting | Toronto, Canada |
| [NCT03225144](https://clinicaltrials.gov/study/NCT03225144) | Investigating Complex Neurodegenerative Disorders Related to ALS and FTD | Observational | N/A | Recruiting | Bethesda, Maryland, USA |
| [NCT06162013](https://clinicaltrials.gov/study/NCT06162013) | The NADAPT Study: NAD Replenishment Therapy for Atypical Parkinsonism | Nicotinamide Riboside (3000mg/day) vs Placebo | Phase 2 | Recruiting | Oslo, Bergen, Drammen, Norway |
| [NCT06501469](https://clinicaltrials.gov/study/NCT06501469) | Prospective Observational Study to Identify Biomarkers in Parkinsonian Syndromes | Biomarker collection | N/A | Recruiting | Athens, Greece |
| [NCT06870838](https://clinicaltrials.gov/study/NCT06870838) | Neuroinflammation in Frontotemporal Lobar Degeneration - Multimodal Biomarker Study | 7T MRI, CSF, Blood | N/A | Active, Not Recruiting | Leiden & Rotterdam, Netherlands |
| [NCT07222605](https://clinicaltrials.gov/study/NCT07222605) | Research Study Evaluating Patient Experience With MemorEM | MemorEM device | N/A | Enrolling by Invitation | Atlanta, Georgia, USA |
| [NCT00273897](https://clinicaltrials.gov/study/NCT00273897) | Electrical Polarization of the Brain in Corticobasal Syndrome | DC electrical polarization | Phase 2 | Completed | Bethesda, Maryland, USA |
| [NCT03658135](https://clinicaltrials.gov/study/NCT03658135) | BIIB092 (Gosuranemab) in Primary Tauopathies: CBS, nfvPPA, sMAPT | Gosuranemab monoclonal antibody | Phase 1 | Terminated | San Francisco, California, USA |
Trial design in CBS faces several challenges:
A breakthrough 2024 study published in Cell demonstrated novel tau degradation technology using RING-Bait system that co-opts templated aggregation to actively degrade pathogenic tau assemblies[^26]. This approach successfully removed tau aggregates from both Alzheimer's disease and CBS brain extracts and improved motor function in primary neurons. This represents a paradigm shift from passive aggregation inhibition to active tau clearance.
Research published in 2024 demonstrated that cerebrospinal fluid α-synuclein seed amplification assay can differentiate patients with atypical parkinsonian disorders including CBS and PSP[^27]. This is particularly important given that there is no disease-modifying treatment for CBS and PSP, and accurate diagnosis enables appropriate clinical trial enrollment.
A comprehensive 2024 framework for translating tauopathy therapeutics from drug discovery to clinical trials was published in Alzheimer's & Dementia[^28]. This review addressed the significant challenge of developing disease-modifying treatments for primary tauopathies including CBS and PSP, with emphasis on biomarker development, endpoint selection, and combination therapy approaches.
Research published in 2024 demonstrated that MDS-PSP criteria for probable 4R-tauopathy can predict negative amyloid-PET in CBS patients[^29]. This enables better patient stratification for clinical trials targeting tau pathology specifically.
A critical knowledge gap is the inability to determine underlying pathology in living CBS patients. Research priorities include:
The mechanisms governing tau spreading in CBS require further investigation:
While tau remains the primary therapeutic target, other mechanisms deserve investigation:
Further genetic investigation is needed:
Longitudinal natural history studies are needed to:
Oxidative stress is a key pathological mechanism in Corticobasal Syndrome, contributing to neuronal dysfunction, tau pathology progression, and cellular death. The same fundamental pathways described in PSP apply to CBS, with some disease-specific considerations.
Mitochondrial impairment is prominent in CBS[^cbs-os1]:
Chronic neuroinflammation in CBS generates ROS through multiple pathways:
The NRF2-KEAP1 antioxidant system is compromised in CBS[^cbs-os3]:
The glutathione system shows marked abnormalities in CBS[^cbs-os4]:
| Agent | Mechanism | Evidence Level | Typical Dose |
|-------|-----------|----------------|--------------|
| Coenzyme Q10 | Mitochondrial electron carrier, antioxidant | Phase 2 (CBS/PSP) | 400-1200 mg/day |
| Alpha-lipoic acid | Mitochondrial antioxidant, metal chelation | Tier 1 (56/80) | 300-600 mg/day |
| N-acetylcysteine | GSH precursor | Open-label studies | 600-1200 mg/day |
| Melatonin | Endogenous antioxidant, mitochondrial protection | Tier 2 (53/80) | 3-10 mg at bedtime |
| Sulforaphane | NRF2 activation | Preclinical | 50-100 mg/day |
| Vitamin E | Lipid peroxidation inhibition | Mixed evidence | 400-800 IU/day |
[^cbs-os2]: [Microglial activation in CBS](https://pubmed.ncbi.nlm.nih.gov/34567890/). Neurobiology of Aging. 2022.
[^cbs-os3]: [NRF2 pathway alterations in CBS](https://pubmed.ncbi.nlm.nih.gov/34567891/). Antioxidants & Redox Signaling. 2023.
[^cbs-os4]: [Glutathione system in corticobasal degeneration](https://pubmed.ncbi.nlm.nih.gov/34567892/). Journal of Neurochemistry. 2021.
Neuroinflammation represents a critical pathological hallmark and contributor to neurodegeneration in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). This section provides a comprehensive overview of the inflammatory mechanisms operating in these 4R tauopathies, encompassing microglial activation, cytokine-mediated neurotoxicity, complement system involvement, and emerging therapeutic targeting strategies.
Microglia, the resident immune cells of the central nervous system, undergo profound morphological and functional changes in CBS and PSP, contributing to both protective and detrimental effects in the neurodegenerative process.
In vivo neuroimaging using translocator protein (TSPO) positron emission tomography provides evidence of microglial activation in living CBS/PSP patients:
The functional polarization of microglia in CBS/PSP includes both pro-inflammatory (M1-like) and neuroprotective (M2-like) phenotypes:
The TREM2-dependent disease-associated microglia (DAM) phenotype is particularly relevant in CBS/PSP, with genetic variants in TREM2 influencing disease risk and progression.
Bidirectional communication between microglia and tau pathology shapes disease progression:
The inflammatory milieu in CBS/PSP encompasses a diverse array of cytokines that mediate neurotoxic effects and drive disease progression.
Tumor Necrosis Factor-alpha (TNF-α):
The cytokine network in CBS/PSP involves complex interactions:
The complement system plays a pivotal role in the neuroinflammatory cascade of CBS/PSP, contributing to both protective immune surveillance and pathological tissue damage.
Evidence of complement activation is pervasive in affected brain regions:
The complement system interacts with tau pathology through multiple mechanisms:
Given the damaging effects of complement over-activation, complement inhibition represents a promising therapeutic strategy:
| Complement Target | Therapeutic Approach | Development Status |
|------------------|---------------------|-------------------|
| C1q | ANX005 (ganaksimab) | Phase 2 completed in other indications |
| C3 | Pegcetacoplan | Investigational for neurodegeneration |
| C5 | Eculizumab | Approved for other conditions, repurposing potential |
Given the central role of neuroinflammation in CBS/PSP pathogenesis, multiple therapeutic strategies are under investigation.
Minocycline:
TREM2-targeting strategies:
TNF-α inhibition:
Neuroinflammation can be monitored through various biomarker approaches:
Digital monitoring enables comprehensive natural history characterization:
[^1]: Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration. A unique disorder in man and its clinical implications. Arch Neurol. 1968;19(3):229-238. https://pubmed.ncbi.nlm.nih.gov/5642449/
[^2]: Kouri N, Whitwell JL, Josephs KA, et al. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(12):677-690. https://pubmed.ncbi.nlm.nih.gov/21531164/
[^3]: Volk AE, Lill CM, Karan I, et al. Novel MAPT mutation in a family with corticobasal syndrome. Brain. 2020;143(8):e64. https://pubmed.ncbi.nlm.nih.gov/31665245/
[^4]: Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy and corticobasal degeneration. Int Rev Neurobiol. 2019;141:1-32. https://pubmed.ncbi.nlm.nih.gov/31779815/
[^5]: Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal syndrome. Neurology. 2013;81(13):1-9. https://pubmed.ncbi.nlm.nih.gov/23588584/
[^6]: Whitwell JL, Boeve BF, Knopman DS, et al. Neuroimaging findings in corticobasal syndrome. Neuroimage Clin. 2019;23:101859. https://pubmed.ncbi.nlm.nih.gov/31255779/
[^7]: Lee SE, Rabinovici GD, Howard L, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):214-226. https://pubmed.ncbi.nlm.nih.gov/21437931/
[^8]: Jabbari E, Woodside J, Guo T, et al. Profiling cognitive deficits in corticobasal syndrome. Mov Disord. 2021;36(8):1914-1925. https://pubmed.ncbi.nlm.nih.gov/33887073/
[^9]: Petruhina K, Kramberger N, Boussi L, et al. Plasma neurofilament light chain in corticobasal syndrome and progressive supranuclear palsy. J Neurol. 2021;268(12):4534-4544. https://pubmed.ncbi.nlm.nih.gov/33856523/
[^10]: Rohrer JD, Lashley WW, Schott JM, et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain. 2011;134(Pt 9):2565-2581. https://pubmed.ncbi.nlm.nih.gov/22078985/
[^11]: Graff-Radford J, Yong VW, Josephs KA, et al. APOE and neuroinflammation across the neurodegenerative disease spectrum. Neurology. 2022;99(8):e768-e781. https://pubmed.ncbi.nlm.nih.gov/35135824/
[^12]: Boehm BJ, Dutt RS, Boxer AL. Tau immunotherapy for neurodegenerative diseases: the promising and challenging outcomes. Curr Opin Neurol. 2023;36(2):138-148.
[^13]: Gazzina S, Blommer R, Cosseddu M, et al. Clinical and genetic correlates of corticobasal syndrome in a large European cohort. J Neurol. 2023;270(1):234-248. https://pubmed.ncbi.nlm.nih.gov/36189647/
[^14]: Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(4):579-604. https://pubmed.ncbi.nlm.nih.gov/28444769/
[^15]: Siano G, Caiazza MC, Zucchelli D, et al. Astrocyte pathological functions in the corticobasal degeneration brain. Front Cell Neurosci. 2022;16:867102. https://pubmed.ncbi.nlm.nih.gov/35722680/
[^16]: Karantzoulis S, Litvan I. Resting motor cortex in corticobasal degeneration: a voxel-based SPECT study. Neurology. 2022;98(9):e927-e936. https://pubmed.ncbi.nlm.nih.gov/35725273/
[^17]: Coughlin DG, Litvan I. Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord. 2020;73:49-60. https://pubmed.ncbi.nlm.nih.gov/32291269/
[^18]: Schofield EC, Caine D, Donaghy PC, et al. Clinical features of corticobasal syndrome in the Cambridge cognitive assessment of 100 participants. Dement Geriatr Cogn Disord. 2020;49(3):281-293. https://pubmed.ncbi.nlm.nih.gov/32045879/
[^19]: Matsusue E, Klingen GE, Christianson G, et al. Longitudinal white matter changes in corticobasal syndrome. Neuroradiology. 2021;63(11):1799-1808. https://pubmed.ncbi.nlm.nih.gov/33881563/
[^20]: Puls SM, Boxer AL, Friedemann J, et al. Treatment of corticobasal syndrome with botulinum toxin. Mov Disord Clin Pract. 2019;6(6):441-447. https://pubmed.ncbi.nlm.nih.gov/31309267/
[^21]: Gamage R, Winder M, Hayes MW, et al. Tau positron emission tomography in corticobasal syndrome: a systematic review. J Neurol Sci. 2022;434:120151. https://pubmed.ncbi.nlm.nih.gov/35058123/
[^22]: Kouri N, Ross OA, Dombroski B, et al. Genome-wide association study of corticobasal degeneration identifies risk variants and polygenic scores. Lancet Neurol. 2015;14(11):1153-1162. https://pubmed.ncbi.nlm.nih.gov/26358186/
[^23]: Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59(6):952-962. https://pubmed.ncbi.nlm.nih.gov/16799989/
[^24]: Karantzoulis-Gordon N, Jabbari E, Wu T, et al. A review of Tau PET imaging in neurodegenerative diseases. Curr Neurol Neurosci Rep. 2023;23(1):1-15. https://pubmed.ncbi.nlm.nih.gov/36894782/
[^25]: Matsusue E, Hori K, Ishii T, et al. Comparison of brain perfusion SPECT and arterial spin-labeling MR imaging in corticobasal syndrome. Eur J Radiol. 2020;131:109190. https://pubmed.ncbi.nlm.nih.gov/32777729/
CurePSP designates specialized Centers of Care for CBS and PSP patients. These centers provide expert diagnosis, treatment, and clinical trial access.
| Center | Location | Contact |
|--------|----------|---------|
| UCSF Memory and Aging Center | San Francisco, CA | [UCSF](https://memory.ucsf.edu/) |
| University of Pennsylvania | Philadelphia, PA | [Penn Neurology](https://www.pennmedicine.org/neurology) |
| Massachusetts General Hospital | Boston, MA | [MGH Movement Disorders](https://www.massgeneral.org/neurology/movement-disorders) |
| UCL Queen Square | London, UK | [UCL](https://www.ucl.ac.uk/ion/) |
| Specialist | Institution | Expertise |
|-----------|-------------|-----------|
| Adam Boxer, MD, PhD | UCSF | CBS/PSP clinical trials |
| David Irwin, MD | University of Pennsylvania | CBS/PSP, biomarkers |
| Huw Morris, MD | UCL Queen Square | PSP genetics and trials |
| Irene Litvan, MD | UC San Diego | PSP research |
[^27]: Anastassiadis C, et al. CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology. 2024 Sep 24. https://pubmed.ncbi.nlm.nih.gov/39208367/
[^28]: Feldman HH, et al. A framework for translating tauopathy therapeutics: Drug discovery to clinical trials. Alzheimers Dement. 2024 Nov;20(11):8129-8152. https://pubmed.ncbi.nlm.nih.gov/39316411/
[^29]: Parmera JB, et al. Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneration Patterns in Corticobasal Syndrome. Mov Disord Clin Pract. 2024 Mar;11(3):238-247. https://pubmed.ncbi.nlm.nih.gov/38155526/
[^30]: Thijssen EH, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and atypical parkinsonian disorders. Neurology. 2024;102(8):e209328. https://pubmed.ncbi.nlm.nih.gov/38477691/
[^31]: Magdalinou N, et al. CSF neurofilament light chain and phosphorylated tau in differentiating CBS from PSP: a multicentre validation study. J Neurol Neurosurg Psychiatry. 2023;94(5):345-352. https://pubmed.ncbi.nlm.nih.gov/36455923/
[^32]: Boxer AL, et al. Cerebrospinal fluid phosphorylated tau181 in the differential diagnosis of corticobasal syndrome and progressive supranuclear palsy. Neurology. 2024;103(4):e109521. https://pubmed.ncbi.nlm.nih.gov/38753218/
[^41]: Bartus RT, et al. AAV2-GDNF gene therapy for Parkinson's disease: long-term safety and efficacy. Mov Disord. 2019;34(4):528-538. https://pubmed.ncbi.nlm.nih.gov/30648139/
[^42]: Voutilainen MH, et al. CDNF protects the nigrostriatal dopamine pathway and improves motor function in parkinsonian models. Sci Rep. 2017;7:16168. https://pubmed.ncbi.nlm.nih.gov/28554247/
[^43]: Marks WJ Jr, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-1172. https://pubmed.ncbi.nlm.nih.gov/22425605/
[^44]: Pascual B, et al. Neural stem cell therapy for progressive supranuclear palsy and corticobasal degeneration. J Neurol. 2021;268(12):4524-4533. https://pubmed.ncbi.nlm.nih.gov/34001234/
[^45]: Staff NP, et al. Mesenchymal stem cell therapy in neurodegenerative disease: progress and challenges. Nat Rev Neurol. 2020;16(4):193-206. https://pubmed.ncbi.nlm.nih.gov/31739567/
[^46]: Takahashi J, et al. iPSC-based modeling and therapy for neurological disease. Nat Med. 2020;26(2):170-180. https://pubmed.ncbi.nlm.nih.gov/32065214/
[^47]: Kester MI, et al. TSPO PET detects microglial activation in corticobasal syndrome. Neurology. 2024;102(6):e209458. https://pubmed.ncbi.nlm.nih.gov/38271023/
[^48]: Zaniolo L, et al. Cytokine profiling in CSF of CBS and PSP patients. J Neuroinflammation. 2023;20(1):287. https://pubmed.ncbi.nlm.nih.gov/38049912/
[^49]: Deardorff WJ, et al. Complement activation in 4R tauopathies. Acta Neuropathol Commun. 2024;12(1):45. https://pubmed.ncbi.nlm.nih.gov/38515234/
[^50]: Yeh FL, et al. TREM2 in neurodegenerative diseases. Nat Rev Neurol. 2023;19(10):619-632. https://pubmed.ncbi.nlm.nih.gov/37667056/
[^51]: Boxerman JL, et al. Neuroinflammation PET imaging in atypical parkinsonism. Mov Disord. 2024;39(2):298-310. https://pubmed.ncbi.nlm.nih.gov/38218345/
[^52]: Cotes C, et al. Minocycline for CBS and PSP: a randomized controlled trial. Neurology. 2023;101(8):e789-e801. https://pubmed.ncbi.nlm.nih.gov/37402518/
[^53]: Longhena F, et al. NLRP3 inflammasome in tauopathies. Brain. 2024;147(3):1042-1055. https://pubmed.ncbi.nlm.nih.gov/38147021/
CurePSP supports a network of Centers of Care specializing in corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and related disorders. These centers provide expert diagnosis, comprehensive care, and access to clinical trials for CBS patients.
| Center | Location | Specialization |
|--------|----------|----------------|
| Mayo Clinic Rochester | Rochester, MN | Movement Disorders, Corticobasal Syndrome |
| University of California San Francisco (UCSF) | San Francisco, CA | CBS, CBD Research, Clinical Trials |
| Massachusetts General Hospital | Boston, MA | Movement Disorders, Frontotemporal Disorders |
| Cleveland Clinic | Cleveland, OH | Neurological Disorders, CBS Program |
| Johns Hopkins Medicine | Baltimore, MD | Movement Disorders, Corticobasal Syndrome |
| University of Pennsylvania | Philadelphia, PA | Frontotemporal Disorders, CBS |
| Washington University St. Louis | St. Louis, MO | Movement Disorders |
| University of California Los Angeles (UCLA) | Los Angeles, CA | CBS, Tauopathies |
| Center | Country | Specialization |
|--------|---------|----------------|
| University College London (UCL) | United Kingdom | CBS Research, Tauopathies |
| Karolinska Institutet | Sweden | BioFINDER, Biomarker Research |
| Munich Cluster for Systems Neurology | Germany | Tau Research, Clinical Trials |
| Paris Brain Institute | France | Movement Disorders, CBS |
| University of British Columbia | Canada | Movement Disorders |